David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
|Articles|December 1, 1995
The American Journal of Managed Care
- November/December 1995
- Volume 1
- Issue 3
Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study
Advertisement
Articles in this issue
almost 31 years ago
Cost-Benefit Analysis of Epilepsy Treatment by the Neurologistalmost 31 years ago
Appropriate Use of Abdominal Ultrasonography in Two Hospitalsalmost 31 years ago
Long-Term Management of Gastroesophageal Reflux Diseasealmost 31 years ago
Life-Effectiveness Analysis -- More Shadow Than Light?almost 31 years ago
The Role of the AHCPR in Clinical Guidelines DevelopmentAdvertisement
Related to this article
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
Medicare’s GLP-1 Bridge program aims to expand obesity treatment, but eligibility hurdles and drug costs leave many seniors paying hundreds monthly.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Managed Care Keeps Pace With Policy as AMCP Nexus Heads to San Diego
5